I think LymPro is now questionable as a relevant r
Post# of 30028
Posted On: 07/31/2014 5:44:14 PM
I think LymPro is now questionable as a relevant revenue source in the next six months to a year.
The ultimate responsibility of the C.E.O. is to keep the doors open. Lincoln Park Capital is still obligated to purchase an additional approximately $18,000,000 worth of shares. The lowest price that they can pay for these shares is .04/share. The company would need 450,000,000 shares if all the shares were purchased at .04 which hopefully won't be the case. Even at .08/share 225,000,000 shares would be needed.
As I see it the only option available to the company is to increase the number of authorized shares to either 1.5B or 2.0B. If this is done I think the share price could fall to the .05 range.
No one knows for certain what will happen. I'm certainly not as smart as some of the other posters on the board but this is my best guess as to what might happen.
The ultimate responsibility of the C.E.O. is to keep the doors open. Lincoln Park Capital is still obligated to purchase an additional approximately $18,000,000 worth of shares. The lowest price that they can pay for these shares is .04/share. The company would need 450,000,000 shares if all the shares were purchased at .04 which hopefully won't be the case. Even at .08/share 225,000,000 shares would be needed.
As I see it the only option available to the company is to increase the number of authorized shares to either 1.5B or 2.0B. If this is done I think the share price could fall to the .05 range.
No one knows for certain what will happen. I'm certainly not as smart as some of the other posters on the board but this is my best guess as to what might happen.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼